CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-25 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −3,097 | $36.57 | $113K | 359,036 |
| 2026-09-14 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +125,000 | 362,133 | ||
| 2026-08-12 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +62,500 | 237,133 | ||
| 2026-06-25 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −2,867 | $45.03 | $129K | 174,633 |
| 2026-06-22 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +62,500 | 177,500 | ||
| 2026-02-03 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +115,000 | 115,000 | ||
| 2025-03-17 | Wiley Matthew T. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +350,000 | 350,000 |
Page 1 of 1 · 7 trades